Michael Hunt BSc ACA, Chief Executive Officer

Michael Hunt joined ReNeuron as Chief Financial Officer and was appointed Chief Operating Officer in September 2003 and Chief Executive Officer in July 2005. Prior to ReNeuron, he spent six years at Biocompatibles International plc where he held a number of senior financial and general management positions. His early industrial career was spent at Bunzl plc. He sits on the BioIndustry Association’s Cell Therapy and Regenerative Medicine Advisory Committee and its Finance and Tax Advisory Committee. He is a Senior Industry Group member of the UK Government’s Office for Life Sciences and a member of the UK Technology Strategy Board’s RegenMed Advisory Group. He read economics at University College London and qualified as a chartered accountant with Ernst & Young in London.

Dr. Sinden is a scientific co-founder of ReNeuron. Prior to joining ReNeuron as Chief Scientific Officer in October 1998, he was Reader in Neurobiology of Behaviour at the Institute of Psychiatry at Kings College London. He graduated in Psychology from the University of Sydney and completed a Ph.D. in Neuroscience from the University of Paris at the College de France. He subsequently held post-doctoral appointments at Oxford University and the Institute of Psychiatry prior to joining the permanent staff of the Institute in 1987. Dr. Sinden is a member of the Royal Society of Medicine, the Society for Neuroscience and the International Society for Cellular Therapies. He sits on the Industry Committee of the International Society for Stem Cell Research, the Scientific Advisory Board of the Minda de Gunzburg Center for Ocular Regeneration, Schepens Eye Research Institute at Harvard Medical School, and the Expert Working Group on Cell and Gene Therapies for the Bioindustry Organization BioSafe Committee.

Dr Kenny Pollock BSc, Ph.D., Head of Cell Development

Dr. Pollock joined ReNeuron Limited in September 2001 as Head of Molecular Pharmacology. In 2002 he took over management of the Cell Biology group and joined the Management Committee in January 2004. As a graduate and post-graduate of Glasgow University (Department of Pharmacology), his core research interests for the last twenty years have been in cell signalling and cell biology. Following post-doctoral posts at the University of Cambridge and with AstraZeneca plc, he worked for eleven years in drug discovery research with Aventis Pharmaceuticals, Inc. Prior to joining ReNeuron, he worked as a project manager with Incyte Corporation developing pharmacogenomics databases. He now manages all internal and external development cell biology projects.

Dr Paul Stroemer BSc Ph.D., Head of Pre-clinical Research

Dr. Stroemer joined ReNeuron in September 1998 as a researcher and since 2004 has been responsible for managing both in-house and contracted pre-clinical development programs. He completed a Ph.D. at the University of Texas Medical Branch in Galveston, developing pharmacotherapies in the promotion of behavioural recovery and anatomical plasticity after stroke. Prior to joining ReNeuron, he undertook post-doctoral research at the University of Manchester examining the neuroprotective effects of reducing inflammatory responses in the brain after stroke.He now manages both internal and external pre-clinical projects.

Caroline McManamon BSc Hons, MTOPRA Head of Regulatory Affairs

Caroline McManamon joined ReNeuron as Head of Regulatory Affairs in April 2011, having previously worked with the company over a period of 7 years as a CMC and regulatory advisor. She graduated in Microbiology at Newcastle upon Tyne University and has 24 years experience in Regulatory Affairs, mainly in the development of biological medicines. Caroline has worked in small to medium sized companies (Evans Medical, Medeva) and as a senior consultant with various CROs (QuadraMed, Fulcrum Pharma, NDA) and latterly as Deputy Director Regulatory Affairs in NDA UK where she developed the company’s expertise in Advanced Therapy Medicinal Products, working with Stem Cell companies in Europe and USA.

Professor Jack Price BA Ph.D., Principal Scientific Consultant

Professor Price is Professor of Developmental Neurobiology and Head of the Centre for the Cellular Basis of Behaviour at the Institute of Psychiatry, Kings College London. He obtained a Ph.D. in Neuroscience from University College London before a period of post-doctoral research at the Massachusetts Institute of Technology. He then directed a research group at the National Institute for Medical Research, Mill Hill. He moved to SmithKline Beecham Pharmaceuticals in 1994, where he became Director for Molecular Neurobiology. Since 1998, he has been on the permanent staff of the Institute of Psychiatry and Consultant to ReNeuron Limited.

Patrick Huggins FCCA, Head of Finance and Company Secretary

Patrick Huggins was appointed as Head of Finance and Company Secretary in May 2010 having previously worked for ReNeuron in an interim capacity. He qualified as a Certified Accountant in 1984 and has spent the majority of his career in fast growth companies within the SME sector.